AzurRx BioPharma (NASDAQ: AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, … Continue reading “AzurRx BioPharma Inc. (NASDAQ: AZRX) Attends 31st Annual ROTH Conference”
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, this morning issued a clinical development and strategic corporate update. In the update, the company reports that the first patients have been dosed in its phase II OPTION study to investigate MS1819-SD in cystic fibrosis (“CF”) patients with … Continue reading “NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) Issues Corporate Update; Reports First Patients Dosed in Phase II OPTION Study”
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in … Continue reading “AzurRx BioPharma, Inc. (AZRX) Starts Presentation at LD Micro Main Event”
AzurRx BioPharma Inc. (NASDAQ: AZRX) today released positive results for preclinical testing of its AZX1103 product, a b-lactamase enzyme combination treatment designed to prevent hospital-acquired gastro-intestinal infections for patients receiving antibiotics in the hospital setting. As stated in the press release, “The series of preclinical studies investigated oral delivery of AZ1103 using three different capsule … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Releases Positive AZX1103 Preclinical Results”
AzurRx BioPharma (NASDAQ: AZRX) is a biopharmaceutical company engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company’s lead development program MS1819 recombinant lipase for exocrine pancreatic insufficiency and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered … Continue reading “AzurRx BioPharma, Inc. (NASDAQ: AZRX) Starts Presentation at 30th Annual ROTH Conference”
AzurRx BioPharma, Inc. (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, this morning announced that, in partnership with French pharmaceutical firm Mayoly Spindler, it has enrolled three new patients to its phase IIA study of MS1819-SD for patients with exocrine pancreatic insufficiency caused by chronic pancreatitis. With these … Continue reading “NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) Adds Three New Patients to Phase IIA Study of MS1819-SD”
Development stage biopharmaceutical company AzurRx BioPharma, Inc. (NASDAQ: AZRX) yesterday announced that it has received proceeds of approximately $2.04 million from the exercise of a total of 851,987 outstanding common stock purchase warrants. Per the update, the exercise transactions were negotiated with warrant holders as a means of raising additional working capital and were completed … Continue reading “NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) Secures Proceeds of $2M from Exercise of Outstanding Warrants”
Development stage biopharmaceutical company AzurRx BioPharma, Inc. (NASDAQ: AZRX) this morning announced that the United States Patent and Trademark Office has published patent application number 15/519424, entitled ‘Hybrid Proteinaceous Molecule Capable of Inhibiting at Least One Antibiotic and Pharmaceutical Composition Containing It’, covering the company’s AZX1101 recombinant enzyme for the prevention of antibiotic-induced diarrhea and … Continue reading “NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) Announces Publication of AZX1101 Patent Application”
AzurRx BioPharma (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, NY, … Continue reading “AzurRx BioPharma, Inc. (NASDAQ: AZRX) Starts Presentation at LD Micro Main Event”
AzurRx BioPharma (NASDAQ: AZRX) this morning said it has submitted an Investigational Medicinal Product Dossier (IMPD) for MS1819-SD. The company’s lead product, currently under development as part of a join research and development agreement with Laboratoires Mayoly Spindler, SAS, is a recombinant lipase for the treatment of exocrine pancreatic insufficiency caused by chronic pancreatitis and … Continue reading “NetworkNewsBreaks – AzurRx BioPharma, Inc. (NASDAQ: AZRX) and Mayoly Spindler Submit IMPD in Europe for Lead Product, MS1819-SD”
